Background {#Sec1}
==========

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting intestinal inflammatory disease with an increasing prevalence worldwide \[[@CR1], [@CR2]\]. Crohn' s disease (CD) and ulcerative colitis (UC) are two forms of IBD \[[@CR3]\]. While UC is limited to the colon, CD can affect anywhere along the gastrointestinal tract, most frequently in the distal ileum. The main clinical manifestations are abdominal pain, diarrhea and bloody stool. Besides the intestinal inflammatory involvement and complications that characterize the disease, extraintestinal manifestations (EIMs) occur in up to 40% of IBD patients \[[@CR4]\], involving the eyes, mouth, nerve system, skin, joints, and liver \[[@CR5]\]. Oral lesions precede, coincide with or follow the onset of the intestinal symptoms \[[@CR6]\]. However, the prevalence of oral lesions in IBD varied substantially in previous studies \[[@CR7], [@CR8]\]. Due to poorly understood etiology, there is currently no cure but only temporary relief for IBD patients \[[@CR9]\].

While many potential causes that play a major role in the disease pathogenesis have been identified. These fall into three specific categories: genetic predisposition, the host immune system, as well as environmental factors, such as the gut microbiota dominated by intestinal bacteria \[[@CR10], [@CR11]\]. An emerging theory is that IBD is the result of an abnormal reaction of T-lymphocytes to specific bacterial flora in genetically vulnerable populations \[[@CR12]\]. Compared with healthy individuals, the composition of intestinal bacterial microbiota of IBD patients were imbalance \[[@CR13]\]. The dynamic crosstalk between intestinal epithelial cells (IECs), intestinal microbes and local immune cells reflects one of the essential features of intestinal homeostasis \[[@CR13]\].

Earlier studies documented a high prevalence of periodontitis in patients with IBD \[[@CR14], [@CR15]\]. However, with regard to the markedly different features between CD and UC \[[@CR16]\], information would be lost when they are combined as IBD. Hence, they should be measured separately. Periodontitis is a polymicrobial, biofilm-mediated disease resulting in inflammatory resorption of alveolar bones \[[@CR17]\]. Periodontitis and IBD share the inflammatory processes in its progression, in which the key mediators involved in tissue damage are common, such as some cytokines \[[@CR12], [@CR18]\]. In addition, a high frequency of periodontopathic bacteria such as *Campylobacter rectus, Porphyromonas gingivalis and Tannerella forsythia* have been found among patients with CD \[[@CR19]\]. The periodontal pathogens induced changes of the composition of intestinal microorganisms, and their inflammatory response could cause IECs barrier dysfunction, accentuating the disease \[[@CR20]\].

At present, the relationship between periodontitis and IBD has not been firmly established. Confirming this correlation is critical and would inspire future research on understanding IBD etiology, elucidating the underlying mechanisms, and might lead to novel treatment strategies. Therefore, we conducted a meta-analysis on the association between periodontitis and IBD.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

In this meta-analysis, we followed the method described in the Meta-Analysis of Observational Studies in Epidemiology guidelines \[[@CR21]\]. The following major databases were screened for the following terms: ((((inflammatory bowel disease) OR Crohn's disease) OR ulcerative colitis)) AND ((((((((periodontal diseases) OR gingival diseases) OR periodontitis) OR gingivitis) OR edentulous) OR edentulism) OR tooth loss) OR teeth loss). English-language publications were extracted from Web of Science, PubMed, Cochrane, and Embase; while Chinese-language articles were retrieved from China National Knowledge Infrastructure (CNKI), Wangfang and CQVIP. The search was limited to literature from before August 1, 2019, including primary researches.

Study selection {#Sec4}
---------------

Eligible studies were examined by authors (Yang-yang She and Xiang-bo Kong) independently. Final selection was verified by a third author (Hong-bo Jiang) and disagreements were resolved by discussions. The inclusion criteria of an eligible study were as follow: (1) related to periodontal conditions in patients with IBD; (2) provided at least one of the clinical parameters: bleeding on probing (BOP), clinical attachment loss (CAL), oral plaque index (PI), gingival index (GI), gingival recession (GR), probing pocket depth (PPD), papilla bleeding index (PBI); (3) reported original data; (4) presented cross-sectional studies, cohort studies or case-control studies; (5) Full text in English or Chinese. Case reports, case series, in vitro studies, reviews, abstracts, editorials, and letters were excluded from the selection. In case where multiple publications were based on the same population, the more recent or complete report were considered.

Data extraction {#Sec5}
---------------

Data extraction conducted by Yang-yang She and Xiang-bo Kong was based on a standardized, pre-piloted data extraction form. The extracted information included: (1) last name of the first author, publication year, study location, study design and matched variables, (2) study participant demographics including male to female ratio, mean age, total number of IBD, CD, UC cases and controls, (3) periodontal measures including prevalence of periodontitis and risk estimate, BOP, CAL, GI, GR, PI, PPD, and PBI, (4) pharmacological treatments, (5) smoking status of the IBD patients and controls, (6) adjusted variables.

Quality assessment {#Sec6}
------------------

Newcastle-Ottawa Scale (NOS) was employed to evaluate the methodological quality of the included studies \[[@CR22]\]. Studies with at least five scores were defined as moderate or high methodological quality.

Statistical methods {#Sec7}
-------------------

The estimates (or adjusted estimates if applicable) and the corresponding 95% *confidence interval* (*CI*) between IBD and periodontitis were used to calculate the pooled estimates. If no estimates were available in the studies, the numbers of IBD cases (with periodontitis or not) and controls (with periodontitis or not) were used to calculate the pooled estimates. Forest plots were performed to assess the individual and pooled estimates with the corresponding 95% *CI*. The random effect model would be applied if the Cochrane *Q* statistic with a significant level of *P* \< 0.10 or *I*^*2*^ \> 50% \[[@CR23]\]. The statistical analysis was accomplished with Stata Version 11.0 (Stata Corp, College Station Texas). The *P* values from the two-tailed tests are statistically significant when *P* \< 0.05, except where otherwise specified.

Begg's test and Egger's test were applied to test potential publication bias \[[@CR24]\]. Funnel plot was generated to assess publication bias by the visual inspection of asymmetry. The *P* values for Begg's test and Egger's test less than 0.05 revealed that publication bias existed.

To examine the impact of a single estimate on the pooled estimates, we performed sensitivity analysis by systematically removing one study at a time and recalculating the pooled results.

Results {#Sec8}
=======

Literature selection {#Sec9}
--------------------

The literature search distilled 540 citations from databases of Web of Science, Pubmed, Cochrane, Embase, CNKI, Wangfang and CQVIP. After 200 duplications were excluded, 340 studies remained for further consideration. Of these, 325 citations were excluded after screening the titles or abstracts (Fig. [1](#Fig1){ref-type="fig"}). On this screening, 302 citations were irrelevant, 23 citations were reviews, laboratory experimental investigations, case reports, or conference abstracts which were all excluded. After this screening, 14 articles were chosen for whole text review. Among these, three articles had no controls, another three articles presented no primary data and two articles presented the hazard ratio (HR) of periodontitis among IBD patients and non-IBD participants and these eight were excluded. Six studies \[[@CR25]--[@CR30]\] were included for final meta-analyses. Fig. 1PRISMA flowchart: selection process of studies and results of the literature search for meta-analysis

Study characteristics {#Sec10}
---------------------

Characteristics of the included studies in the meta-analysis were shown in Table [1](#Tab1){ref-type="table"}. All studies were published between 2003 and 2015. The participants were 599 IBD patients and 448 controls. Two studies were conducted in Greece and the other four studies were conducted in Germany, Switzerland, Brazil and Jordan respectively. Adjusted odds ratios (*OR*s) and the corresponding 95% *CI* between IBD and periodontitis were available in three of the six case control studies. The estimates were calculated using the numbers of IBD cases (with periodontitis or not) and controls (with periodontitis or not) in the other three studies. All studies had methodological quality with at least five scores according to the NOS. Table 1Characteristics of included studies in the meta-analysisAuthor (Year)LocationStudy designMatched variablesParticipants (M/F, age)IBD (M/F)Periodontal measuresPharmacological treatmentsSmokingAdjusted variablesNOSGroessner-Schreiber, et al. (2006)GermanyMatched case--control studyAge;sex; smoking statusIBD:62 (24/38, 38.4)Control:59 (24/35, 38.2)CD:46 (18/28)UC: 16 (4/12)PI; BOP; PPD; CAL ≥ 4 mm; CAL ≥ 5 mmCorticosteroids;immunosuppressants;aminosalicylate;anti TNF AntibioticsIBDnonsmokers = 34 (55%);smokers = 25;ex-smokers = 3 (5%)Controlnonsmokers =29 (49%);smokers = 24;ex-smokers = 6 (10%)NA7Zervou, et al. (2007)GreeceMatched case--control studyAge;sexIBD:30Control:47CD: 15 UC: 15PeriodontitisMesalazine;aziathioprineOR (95%CI)nonsmokers = 1.00;smokers = 0.99 (0.11--0.63);ex-smokers = 0.61 (0.06--6.29)Sex;smoking habit;activity duration of disease6Brito, et al. (2008)BrazilMatched case--control studyAgeIBD:179 (64/115)Control:74 (24/50, 40.3)CD:99 (31/68) UC:80 (33/47)BOP; PPD; CAL ≥ 3 mmAminosalicylates; immunomodulaors; corticosteroidds;antibiotics;anti TNF-αCDsmokers = 12 (12.1%);nonsmokers = 63 (63.3%);ex-smokers = 24 (24.3%).UCsmokers = 7 (8.7%);nonsmokers = 38 (47.5%);ex-smokers = 35 (43.8%)Controlsmokers = 9 (12.2%);nonsmokers = 57 (77%);ex-smokers = 8 (10.8%)NA7Habashneh, et al. (2012)JordanCase--control studyNAIBD:160 (94/66)Control:100 (62/38)CD:59 (33/26) UC:101 (61/40)PI; GI; PPD; CAL; GR; BOP; PPD ≥ 3; PPD ≥ 4; CAL ≥ 3; CAL ≥ 4; CAL ≥ 5NACDnonsmokers = 23;smokers = 31;ex-smokers = 5UCnonsmokers = 55;smokers = 17;ex-smokers = 29Controlnonsmokers = 44;smokers = 49;ex-smokers = 7NA7Vavricka, et al. (2013)SwitzerlandMatched case--control studyAgeIBD:113 (65/48, 40.6)Control:113 (58/55, 41.7)CD: 69 (37/32)UC: 44 (28/16)PPD; CAL; CAL at deepest pocket; BOP; PBISystemic steroids;aminosalicylates;Thiopurines;methotrexate;cyclosporine; or tacrolimus;anti-TNF;probiotics;nonsteroidal;antiinflammatory drugCDnonsmokers = 25;smokers = 21;ex-smokers = 3UCnonsmokers = 23;smokers = 2;ex-smokers = 19Controlnonsmokers = 71;smokers = 21;ex-smokers = 21Perianal extraintestinal manifestation; proctitis;teeth brushing≥twice/day;ex-smoking; HBI\>10;CD montreal perianal7Koutsochristou, et al. (2015)GreeceMatched case--control studyAge;Sex;social-economic statusIBD:55 (25/30, 12.3)Control:55 (25/30, 12.2)CD: 36 (18/18)UC: 19 (7/12)GI; CPI (PPD)Aminosalicylate;corticosteroids;anti-TNF;immunomodulatorsCDnonsmokers = 36;UCnonsmokers = 19;Controlnonsmokers = 55NA8

The association of periodontitis prevalence and IBD {#Sec11}
---------------------------------------------------

Among the included studies, the pooled *OR* (95% *CI*) was 3.17 (2.09--4.8) for the association of periodontitis and IBD (Fig. [2](#Fig2){ref-type="fig"}). The pooled *OR* (95% *CI*) was 3.64(2.33--5.67) for the association of periodontitis and CD (Fig. [3](#Fig3){ref-type="fig"}). The pooled *OR* (95% *CI*) was 5.37 (3.30--8.74) for the association of periodontitis and UC (Fig. [4](#Fig4){ref-type="fig"}). Fig. 2Forest plot displaying the meta-analysis results of association between periodontitis and IBDFig. 3Forest plot displaying the meta-analysis results of association between periodontitis and CDFig. 4Forest plot displaying the meta-analysis results of association between periodontitis and UC

IBD and measures of periodontitis {#Sec12}
---------------------------------

Two of the six studies reported oral PI \[[@CR25], [@CR28]\]. Four of the studies reported BOP \[[@CR25], [@CR27]--[@CR29]\] and two on GI \[[@CR28], [@CR30]\]. Five studies provided data on PPD and four on CAL \[[@CR25], [@CR27]--[@CR29]\].

Publication bias {#Sec13}
----------------

No publication bias was observed (Begg's test, z = 0.49, and *P* = 0.624; Egger's test, t = 1.54, and *P* = 0.221). Visual inspection of the funnel plot illustrated a nearly symmetrical distribution, revealing the absence of publication bias (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Funnel plot for publication bias regarding the association between periodontitis and IBD

Sensitivity analysis {#Sec14}
--------------------

The sensitivity analysis showed that the estimates did not vary significantly ranging from 2.85 (95% *CI*: 1.72--4.71) to 3.45 (95% *CI*: 2.18--5.48) when omitting other studies one by one. Generally, the result revealed that no individual study carried enough weight to significantly affect the pooled performance (Fig. [6](#Fig6){ref-type="fig"}). Fig. 6Sensitivity analyses by omitting individual study

Discussion {#Sec15}
==========

In the present meta-analysis, available evidence was summarized to help clarify the association of periodontitis and IBD. Overall, the results showed a positive association of periodontitis with IBD, CD and UC. According to the results, periodontitis was associated with a higher risk of IBD with low heterogeneity. Sensitivity analysis revealed the robustness of our results and the absence of publication bias added the validity of our results.

Accordingly, periodontitis may have an inverse relationship with IBD with different periodontal tissue destruction. Both CD and UC patients showed deeper pockets compared with the controls in the study of Brito, et al \[[@CR29]\]. This is in contrast with Grossner-Schreiber, et al \[[@CR25]\], who found deeper pockets in the control group compared with patients with IBD. Most notably, the average CAL was the most important predictive factor for site progression. More sites with CAL were shown in patients with IBD than health controls by Brito, et al \[[@CR29]\] and Grossner-Schreiber, et al \[[@CR25]\], which highlights the increased risk for periodontal tissue loss among these patients. However, varying extent of periodontal destruction was reflected in UC and CD patients. Compared with UC, CD patients were less vulnerable to CAL and developing sites with CAL ≥ 3 mm. This may indicate a potential difference in the pathophysiology of these two diseases, involving the T helper (Th) cell differentiation. UC is considered to be Th2 disease, while CD has characteristics of a Th1 disease. Another possible explanation for this difference might be due to patients with CD taking markedly more immunomodulators than those with UC \[[@CR29]\].

The observational studies on the the association between periodontitis and IBD are revealing, but it could be interfered by several confounding factors, such as gender, smoking, and medications. Thus, it is necessary to rely on properly adjusted risk estimates. One of the primary drivers of periodontitis is smoking, as proposed by the included studies. It has been shown that those who were ex-smokers and those who were having IBD were prevalent for periodontitis. In patients with CD, ex-smoking and clinical activity were significant risk factors for periodontitis \[[@CR27]\]. But it seems to play a protective role in UC, with a decrease in the expression of proinflammatory Th1/Th17 cytokines in colon \[[@CR31]\]. In addition, in IBD subgroups compared with healthy controls, the existence of perianal extraintestinal manifestations in IBD and proctitis in patients with UC were risk factors for periodontitis \[[@CR27]\]. Furthermore, it is noteworthy that patients with IBD taking immunomodulators had a higher mean value of GI \[[@CR30]\] and increased needs of periodontal treatment. The drug species applied to the treatment of IBD can lead to alterations on periodontal tissues due to the direct toxic effects, as well as indirect immunodepression effects with developing opportunistic infections \[[@CR32]\]. However, in a retrospective cohort study, Chi, et al. \[[@CR33]\] expounded an increased HR for subsequent periodontitis among CD patients when compared to matched controls, where treatment of CD showed protection against periodontitis due to the protective effect of some pharmaceuticals.

Although the etiology of IBD is still unclear, it has been hypothesized that IBD is mediated by chronic inflammation triggered by an environmental stimulus in a genetically primed individual \[[@CR9], [@CR20]\]. Periodontitis is an inflammatory response caused by the stimulation of colonized Gram-negative bacteria \[[@CR9], [@CR20]\]. Microbiological impact has been suggested as a potential factor accountable for the altered predisposition to periodontitis in IBD patients. Van Dyke et al. \[[@CR34]\] reported a microflora composed of Gram-negative bacteria that was consistent with the genus Wolinell in a periodontal microflora of IBD patients. Brito et al. \[[@CR15]\] showed that a high prevalence of *Treponema denticola* and other bacteria, in connection with opportunistic infections in subgingival sites, were found in IBD patients. The severity of periodontitis might be attributable to the crucial microbe-host interaction. Another linkage between periodontitis and IBD is related to immune-inflammatory response. Specifically, a possible role for G protein-coupled receptor 30 (GPR30) and tumor necrosis factor-α (TNF-α) has been implicated \[[@CR35]--[@CR38]\]. The level of TNF-α is elevated in the gastrointestinal tract of CD patients, as well as in the gingival crevicular fluid of periodontitis patients. GPR30 mRNA and protein expression were detectable in the colonic tissues of IBD patients and may play a role in the intestinal inflammatory balance \[[@CR36]\].

At present, our understanding of the mechanism that oral bacteria may contribute to the development of IBD is still evolving. When bacteria find a home in the dental plaque, local pro-inflammatory cytokines produced by the monocytes and macrophages activated by bacteria and their products might enter the systemic circulation \[[@CR39]\]. Focusing on the oral bacteria, so as to initiating new ideas for the treatment of IBD. Treating both local oral and systemic inflammation would probably come under the spotlight for the optimal therapeutic strategies.

While a significant association was found between periodontitis and IBD, there were some limitations in this meta-analysis. First, all the studies included were English publications, leading to a possible language bias. Second, regional, ethnic, age, and diagnostic criteria for periodontitis may also be the sources of heterogeneity, but no further subgroup analysis was performed due to the limited number of studies and subjects. Third, not all six studies included here presented the adjusted estimates between periodontitis and IBD. As a result, potential confounding factors could lead to some bias in the association between periodontitis and IBD. Last but not least, the six studies included here were all case-control studies and no prospective large-scale cohort study has been published. The current data cannot be used to establish a cause-and-effect relationship between IBD and periodontitis. Further intervention studies are needed in order to establish such a causal relationship.

Conclusions {#Sec16}
===========

Collectively, within the limitations of this analysis, result of the current data revealed that periodontitis i1s positively associated with IBD. Future mechanistic studies are necessary to elucidate the potential relationship between periodontitis and IBD.
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